Neuroendocrine Tumors, Searching for New Prognostic Biomarkers Abstract #682

Introduction: Neuroendocrine tumors (NET) of the digestive system were once considered relatively rare, however, the incidence is increasing. New prognostic biomarkers are needed for assessment of tumor behavior to inform patient treatment and improve outcome. The proliferation marker, Ki-67, is used for NET grading. Although classified as low grade, some tumors actually develop metastases.
Aim(s): To determine if other proliferation and/or apoptotic markers could distinguish between metastatic and non-metastatic low grade NET.
Materials and methods: Immunohistochemistry was done for proliferation marker, Mini Chromosome Maintenance 4 (MCM4) and pro-apoptosis marker, Apoptosis-stimulating of p53 protein 2 (ASPP2). Thirty-six low grade digestive NETs either with or without metastasis were studied.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Biomarkers
Presenting Author: Helen Miller

To read results and conclusion, please login ...

Further abstracts you may be interested in

#961 Heterogeneity in the Ki-67 Index of Neuroendocrine Tumors
Introduction: Tumor heterogeneity due to tumor evolution is becoming more widely recognised. Neuroendocrine tumors (NET) are routinely graded using the Ki-67 index based on a single tumor location, however, this could lead to undergrading if the Ki-67 index is higher at the metastatic site.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Pathology, grading, staging
Presenting Author: Helen Miller
Authors: Miller H, Flora R, Drymousis P, Wasan H, ...
#867 Mixed Adenoneuroendocrine Carcinoma (MANECs): A Rare and Challenging Subgroup of Neuroendocrine Neoplasia
Introduction: Mixed Adenoneuroendocrine Carcinomas (MANECs) are rare entities in which at least 30% of neoplastic cells are neuroendocrine in nature (WHO 2010 classification). They result either from two independent lesions that merge together or are unique lesions with different cell populations intermingled.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Pathology, grading, staging
Presenting Author: Dr Conor Mosli Lynch
#1815 MicroRNAs Associated with Small Bowel Neuroendocrine Tumours and Their Metastases
Introduction: Novel molecular analytes are needed in small bowel NETs (SBNETs) to better determine disease aggressiveness and predict treatment response.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Anna Malczewska
#2800 Thymosin Beta 4 Is an Autocrine Mitogen for Neuroendocrine Tumour Cells
Introduction: The most commonly used NET marker chromogranin A, has a sensitivity between 60-90% and a specificity of less than 50%, hence better NET markers are needed. Previous secretome analysis using BON1, NCI-H727 and SHP-77 cell lines has led to the discovery of various candidate NET markers. One such marker is Thymosin Beta 4 (TB4). TB4 is a small 43 amino acid intracellular peptide first isolated from bovine thymus tissue.TB4 or its oxidised form TB4SO are thought to play a role in various aspects of cancer biology including tumour invasion, metastasis and apoptosis.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Ponni Balasundaram
#2870 When It Comes to the Diagnostic of Neuroendocrine Neoplasms (NEN), Not All Markers and Clones Were Made Equal. Assessment of 5 Makers in 466 NEN from 10 Anatomical Sites
Introduction: Histological diagnostic of neuroendocrine neoplasms (NEN) relies on morphological criteria and expression of several neuroendocrine marker assessed by immunohistochemistry. Systematic large evaluation of classical (chromogranin A (chrA), synaptophysin (Syn), CD56) and emerging (chromogranin B (chrB), INSM1) markers are lacking.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: Dr Jerome Cros
Authors: Mamodaly M, Chen R, Cazes A, Guedj N, ...